NTLA's Q4 Loss Narrower Than Estimates, Revenues Increase Y/Y

Intellia Therapeutics (NTLA) incurred a fourth-quarter 2024 loss of $1.24 per share (excluding one-time expenses of change in fair value of investments), which was narrower than the Zacks Consensus Estimate of a loss of $1.32. In the year-ago quarter, Intellia had incurred a loss of $1.46 per share. Including one-time expenses, the company reported a loss of $1.27 per share in the fourth quarter of 2024.See the Zacks Earnings Calendar to stay ahead of market-making news.The company’s total revenues currentl ...